Equities researchers at StockNews.com started coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Get Free Report) in a research note issued on Friday. The brokerage set a “hold” rating on the biotechnology company’s stock.
Nabriva Therapeutics Price Performance
NBRV stock opened at $0.00 on Friday. Nabriva Therapeutics has a 52 week low of $1.22 and a 52 week high of $8.45. The company has a debt-to-equity ratio of 0.12, a current ratio of 0.85 and a quick ratio of 0.52. The stock has a market cap of $6,403.00, a PE ratio of 0.00 and a beta of 1.53.
About Nabriva Therapeutics
Read More
- Five stocks we like better than Nabriva Therapeutics
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Taiwan Semiconductor Soars on Earnings With More Room to Run
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Is Lucid Group Nearing the Bottom? What Investors Should Know
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- 90% Gain Possible? Analysts Are Bullish on Joby Aviation
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.